Premium
A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia
Author(s) -
Yabe Miharu,
Sako Masahiro,
Yabe Hiromasa,
Osugi Yuko,
Kurosawa Hidemitsu,
Nara Taemi,
Tokuyama Mika,
Adachi Souichi,
Kobayashi Chie,
Yanagimachi Masakatsu,
Ohtsuka Yoshitoshi,
Nakazawa Yozo,
Ogawa Chitose,
Manabe Atsushi,
Kojima Seiji,
Nakahata Tatsutoshi
Publication year - 2008
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2008.00931.x
Subject(s) - medicine , fludarabine , busulfan , melphalan , juvenile myelomonocytic leukemia , total body irradiation , transplantation , surgery , hematopoietic stem cell transplantation , chemotherapy , gastroenterology , oncology , stem cell , cyclophosphamide , haematopoiesis , genetics , biology
A pilot study was undertaken using a myeloablative conditioning with fludarabine, busulfan, and melphalan to improve the outcome of HSCT in 10 children, aged six months to six yr, with JMML. All patients were conditioned with oral busulfan (560 mg/m 2 ), fludarabine (120 mg/m 2 ), and melphalan (180–210 mg/m 2 ) prior to HSCT, and received stem cells from bone marrow in seven cases, and from cord blood in three cases. Engraftment was documented in eight patients, whereas graft failure occurred in two, one of whom had received HLA‐mismatched cord blood and other had received bone marrow from HLA‐mismatched mother. Three patients, including two in who graft failure had occurred, relapsed. Five patients developed acute GVHD and two developed chronic GVHD. Seven patients are alive and in remission 27–69 months after transplantation. Thus, our study showed that HSCT following conditioning with fludarabine, busulfan, and melphalan was well tolerated and appeared to be effective for JMML.